Orna's lead program is ORN-252, a clinical trial-ready, CD19 targeting in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases. Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms. The acquisition represents Eli Lilly's strategic investment in novel in vivo cell engineering technology to expand its immunotherapy portfolio.
Cyborg Score Rationale
Orna represents a breakthrough in circular RNA therapeutics with proprietary technology, a lead clinical-stage program (ORN-252), and validation from a major pharma acquisition at $2.4B. The company combines novel RNA engineering with differentiated lipid nanoparticle delivery, addressing large autoimmune disease markets with a first-mover advantage in in vivo CAR-T.
Top Insights
(February 2026) Eli Lilly acquisition announced for up to $2.4B, providing capital and pharma infrastructure for clinical advancement
Proprietary circular RNA (oRNA) technology delivers improved protein expression duration and simplified manufacturing vs. traditional mRNA approaches
Lead program ORN-252 is clinical trial-ready in vivo CAR-T targeting B cell-driven autoimmune diseases—first-mover in in vivo approach
(May 2024) Acquired ReNAgade Therapeutics to strengthen circular RNA platform and expand therapeutic pipeline
Named Competitors
Skyhawk Therapeutics — RNA targeting and modulation for therapeutic development
Sana Biotechnology — In vivo cell engineering and therapeutic development
GeneCentric — Gene therapy and cell engineering platform
Jubilant Therapeutics — Precision therapeutics and drug discovery
Recent Developments
(February 2026) Eli Lilly definitive agreement to acquire Orna for up to $2.4 billion in cash including upfront and milestone payments
(May 2024) Acquired ReNAgade Therapeutics to solidify leadership in circular RNA therapies
(June 2026) Frank Neumann, M.D., Ph.D. appointed Chief Medical Officer with deep expertise in proof-of-concept and clinical evaluation
Open the full interactive Orna Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.